Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$3.43 -1.2%	$3.34	$2.71 ▼ $4.73	$664.60M	1.23	965,340 shs	1.02 million shs
ANAB AnaptysBio	$23.17 -0.9%	$21.29	$12.21 ▼ $41.31	$687.21M	-0.26	638,189 shs	454,361 shs
KALV KalVista Pharmaceuticals	$12.15 -1.3%	$12.50	$7.30 ▼ $15.50	$612M	-0.01	467,801 shs	1.36 million shs
KRRO Korro Bio	$12.35 -0.9%	$14.60	$10.29 ▼ $98.00	$117.01M	2.45	110,736 shs	131,615 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	-1.15%	-2.83%	+8.20%	+4.57%	+13.95%
ANAB AnaptysBio	-0.94%	-0.64%	+11.34%	+35.66%	+1.22%
KALV KalVista Pharmaceuticals	-1.30%	-6.25%	+2.36%	+2.19%	+6.86%
KRRO Korro Bio	-0.88%	-8.79%	-16.55%	-48.02%	-63.25%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABUS Arbutus Biopharma	2.2864 of 5 stars	3.5	0.0	0.0	3.2	2.5	0.6
ANAB AnaptysBio	2.0269 of 5 stars	3.4	0.0	0.0	3.5	1.7	0.6
KALV KalVista Pharmaceuticals	3.8501 of 5 stars	3.6	0.0	4.4	2.3	2.5	0.6
KRRO Korro Bio	1.9152 of 5 stars	3.6	3.0	0.0	1.1	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABUS Arbutus Biopharma	3.00	Buy	$5.50	60.35% Upside
ANAB AnaptysBio	2.80	Moderate Buy	$42.38	82.89% Upside
KALV KalVista Pharmaceuticals	3.13	Buy	$24.83	104.39% Upside
KRRO Korro Bio	3.29	Buy	$102.43	729.38% Upside

Current Analyst Ratings Breakdown

Latest KRRO, ANAB, KALV, and ABUS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/4/2025	ANAB AnaptysBio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$22.00 ➝ $38.00
5/29/2025	ANAB AnaptysBio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$40.00
5/28/2025	ANAB AnaptysBio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $90.00
5/13/2025	KRRO Korro Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00
5/13/2025	KRRO Korro Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$155.00 ➝ $90.00
5/8/2025	KRRO Korro Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$115.00 ➝ $100.00
5/6/2025	ANAB AnaptysBio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$52.00 ➝ $54.00
5/1/2025	ANAB AnaptysBio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$40.00 ➝ $40.00
4/29/2025	KRRO Korro Bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/28/2025	KRRO Korro Bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$74.00
4/16/2025	KRRO Korro Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$25.00

(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABUS Arbutus Biopharma	$6.17M	106.47	N/A	N/A	$0.51 per share	6.73
ANAB AnaptysBio	$91.28M	7.46	N/A	N/A	$2.33 per share	9.94
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	$4.86 per share	N/A
KRRO Korro Bio	$2.27M	51.09	N/A	N/A	$17.12 per share	0.72

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABUS Arbutus Biopharma	-$69.92M	-$0.41	N/A	N/A	N/A	-1,196.64%	-75.51%	-55.81%	8/7/2025 (Estimated)
ANAB AnaptysBio	-$145.23M	-$4.85	N/A	N/A	N/A	-125.70%	-282.47%	-30.79%	8/4/2025 (Estimated)
KALV KalVista Pharmaceuticals	-$126.64M	-$3.72	N/A	N/A	N/A	N/A	-104.25%	-78.69%	7/10/2025 (Estimated)
KRRO Korro Bio	-$83.58M	-$9.44	N/A	N/A	N/A	N/A	-51.64%	-37.94%	8/12/2025 (Estimated)

Latest KRRO, ANAB, KALV, and ABUS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/10/2025	Q4 2025	KALV KalVista Pharmaceuticals	-$0.83	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	ABUS Arbutus Biopharma	-$0.09	-$0.13	-$0.04	-$0.13	$2.54 million	$1.76 million
5/7/2025	Q1 2025	KRRO Korro Bio	-$2.60	-$2.49	+$0.11	-$2.49	$0.13 million	$2.55 million
5/5/2025	Q1 2025	ANAB AnaptysBio	-$1.30	-$1.28	+$0.02	-$1.28	$15.27 million	$27.77 million
3/27/2025	Q4 2024	ABUS Arbutus Biopharma	-$0.08	-$0.07	+$0.01	-$0.07	$2.20 million	$1.57 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABUS Arbutus Biopharma	N/A	N/A	N/A	N/A	N/A
ANAB AnaptysBio	N/A	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KRRO Korro Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABUS Arbutus Biopharma	0.04	6.01	6.01
ANAB AnaptysBio	N/A	8.25	8.25
KALV KalVista Pharmaceuticals	N/A	10.44	10.44
KRRO Korro Bio	N/A	9.41	9.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABUS Arbutus Biopharma	43.79%
ANAB AnaptysBio	N/A
KALV KalVista Pharmaceuticals	N/A
KRRO Korro Bio	13.18%

Insider Ownership

Company	Insider Ownership
ABUS Arbutus Biopharma	20.30%
ANAB AnaptysBio	33.50%
KALV KalVista Pharmaceuticals	10.50%
KRRO Korro Bio	4.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABUS Arbutus Biopharma	90	191.53 million	152.65 million	Optionable
ANAB AnaptysBio	100	29.38 million	19.54 million	Optionable
KALV KalVista Pharmaceuticals	100	49.72 million	44.50 million	Optionable
KRRO Korro Bio	70	9.39 million	8.96 million	No Data

KRRO, ANAB, KALV, and ABUS Headlines

Recent News About These Companies

Cantor Fitzgerald Estimates Korro Bio FY2026 Earnings

June 12, 2025 | americanbankingnews.com

Cantor Fitzgerald Predicts Korro Bio FY2026 Earnings

June 10, 2025 | marketbeat.com

Korro Bio, Inc. (NASDAQ:KRRO) Receives Consensus Rating of "Buy" from Analysts

June 3, 2025 | marketbeat.com

Millennium Management LLC Has $3.65 Million Stake in Korro Bio, Inc. (NASDAQ:KRRO)

June 1, 2025 | marketbeat.com

Woodline Partners LP Invests $3.89 Million in Korro Bio, Inc. (NASDAQ:KRRO)

May 27, 2025 | marketbeat.com

Brokers Offer Predictions for Korro Bio FY2025 Earnings

May 21, 2025 | marketbeat.com

Korro to Participate in Upcoming Investor Conferences

May 14, 2025 | globenewswire.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Veracyte (VCYT), Schrodinger (SDGR) and Korro Bio (KRRO)

May 14, 2025 | theglobeandmail.com

Korro Bio to Cut 20% of Workforce

May 7, 2025 | marketwatch.com

Korro Bio to Cut 20% of Workforce

May 7, 2025 | marketwatch.com

Korro Reports First Quarter 2025 Financial Results and Provides Business Updates

May 7, 2025 | globenewswire.com

Cantor Fitzgerald Initiates Coverage of Korro Bio (KRRO) with Overweight Recommendation

April 30, 2025 | msn.com

Chardan Capital Initiates a Buy Rating on Korro Bio (KRRO)

April 17, 2025 | markets.businessinsider.com

Korro Bio initiated with a Buy at Chardan

April 17, 2025 | markets.businessinsider.com

Chardan Capital Initiates Coverage of Korro Bio (KRRO) with Buy Recommendation

April 17, 2025 | msn.com

Piper Sandler Sticks to Their Buy Rating for Korro Bio (KRRO)

April 11, 2025 | markets.businessinsider.com

Korro Bio appoints Loic Vincent as Chief Scientific Officer

April 2, 2025 | markets.businessinsider.com

Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer

April 1, 2025 | globenewswire.com

Korro Bio: Promising Early Stage RNA Editing Company

March 28, 2025 | seekingalpha.com

Korro Bio Reports 2024 Financial Results and Progress

March 21, 2025 | tipranks.com

Analysts Offer Insights on Healthcare Companies: Avalo Therapeutics (AVTX) and Korro Bio (KRRO)

March 20, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KRRO, ANAB, KALV, and ABUS Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

$3.43 -0.04 (-1.15%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$3.46 +0.03 (+1.02%)

As of 06/20/2025 05:55 PM Eastern

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

AnaptysBio NASDAQ:ANAB

$23.17 -0.22 (-0.94%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$23.16 -0.01 (-0.02%)

As of 06/20/2025 06:07 PM Eastern

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

KalVista Pharmaceuticals NASDAQ:KALV

$12.15 -0.16 (-1.30%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$12.56 +0.41 (+3.37%)

As of 06/20/2025 07:15 PM Eastern

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

Korro Bio NASDAQ:KRRO

$12.35 -0.11 (-0.88%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$12.37 +0.02 (+0.16%)

As of 06/20/2025 04:09 PM Eastern

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time